Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2023 · 10-K
Revenue$2.09M$2.09M+9.0% vs Q4 2022 Net Income-$4.78M-$4.78MN/M vs Q4 2022 EPS Diluted-$0.03-$0.03N/M vs Q4 2022 Gross Profitderived$1,832,000+1.0% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income-$6,362,000N/M Operating Cash Flowderived-$6,019,000N/M Free Cash Flowderived-$6,110,000N/M Margins · derivedGross margin87.7%−6.9 pt vs Q4 2022
Operating margin-304.7%+42.0 pt vs Q4 2022
Net margin-228.7%+103.1 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 7, 2024 · 67 d after period end